LQDA Liquidia Corp

Nasdaq liquidia.com


$ 25.00 $ 1.16 (5 %)    

Friday, 31-Oct-2025 19:41:16 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 24.36
$ 23.39
$ 22.16 x 50
$ 25.15 x 200
$ 23.04 - $ 24.72
$ 9.71 - $ 29.94
3,088,521
na
2.08B
$ 1.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-19-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-20-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-liquidia-maintains-35-price-target

HC Wainwright & Co. analyst Andrew S. Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $35 price target.

 liquidia-to-present-new-liq861-data-from-ascent-trial-at-chest-2025-annual-meeting

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiop...

 jefferies-assumes-liquidia-at-buy-announces-price-target-of-43

Jefferies analyst Amy Li assumes Liquidia (NASDAQ:LQDA) with a Buy rating and announces Price Target of $43.

 raymond-james-maintains-strong-buy-on-liquidia-raises-price-target-to-41

Raymond James analyst Ryan Deschner maintains Liquidia (NASDAQ:LQDA) with a Strong Buy and raises the price target from $33 ...

 wells-fargo-maintains-overweight-on-liquidia-raises-price-target-to-31

Wells Fargo analyst Tiago Fauth maintains Liquidia (NASDAQ:LQDA) with a Overweight and raises the price target from $25 to $31.

 why-is-liquidia-stock-trading-higher-on-tuesday

Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance...

 in-july-and-august-of-2025-liquidia-analyzed-interim-data-from-the-52-week-prospective-open-label-ascent-study-which-fully-enrolled-54-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild

Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints. The tolerability profile o...

 earnings-preview-for-liquidia
Earnings Preview For Liquidia
08/11/2025 15:04:05

 wells-fargo-maintains-overweight-on-liquidia-raises-price-target-to-25

Wells Fargo analyst Tiago Fauth maintains Liquidia (NASDAQ:LQDA) with a Overweight and raises the price target from $23 to $25.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION